A Case of Sunitinib-Associated Thrombotic Thrombocytopenic Purpura.
- Author:
Eun Jin KIM
1
;
Yun Mi CHOI
;
Sin Won LEE
;
Yeon Jung HA
;
Jae Lyun LEE
Author Information
1. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. jaelyun@amc.seoul.kr
- Publication Type:Case Report
- Keywords:
Sunitinib;
Thrombotic thrombocytopenic purpura;
Hemolytic uremic syndrome
- MeSH:
Anemia, Hemolytic;
Carcinoma, Renal Cell;
Cough;
Disease Progression;
Female;
Fever;
Hemolytic-Uremic Syndrome;
Humans;
Indoles;
Niacinamide;
Phenylurea Compounds;
Plasmapheresis;
Purpura, Thrombotic Thrombocytopenic;
Pyrroles;
Recurrence;
Thrombocytopenia;
Thymine Nucleotides
- From:Korean Journal of Medicine
2013;84(2):303-307
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome (TTP-HUS) is an acute condition with abnormalities of multiple organ systems. It is characterized by microangiopathic hemolytic anemia and thrombocytopenia. Several chemotherapeutic agents have been implicated in causing TTP-HUS. We report a case of TTP-HUS during treatment with sunitinib in a patient with metastatic renal cell carcinoma. A 53-year-old woman visited our hospital for fever and cough. She was diagnosed with sunitinib-induced TTP. Discontinuation of sunitinib and plasmapheresis improved her TTP. When she experienced disease progression after a prolonged period without treatment, sorafenib was tried, resulting in a partial response without recurrence of TTP-HUS.
